Short answer
OptimizeRx Corp (OPRX) filed an 8-K current report with the SEC on March 5, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events). Maturity extended 2 years to Oct 11, 2029, reducing near-term refinancing risk.
OptimizeRx Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Maturity extended 2 years to Oct 11, 2029, reducing near-term refinancing risk
- Share buyback authorized up to $10M, permitted through Mar 15, 2027: signals management confidence in valuation
- 1% prepayment premium extended through Oct 11, 2027, limiting early refinancing flexibility
Item 2.02 · Results of Operations and Financial Condition
- Q4 and full-year 2025 results reported; detailed figures in Exhibit 99.1 press release
- New $10M share repurchase program announced alongside earnings: signals management confidence in valuation
- 2026 guidance updated; forward outlook disclosed in same release
Item 8.01 · Other Events
- Board authorized $10M share buyback program, effective March 12, 2026, expiring March 15, 2027 or upon full utilization
- Repurchases funded via existing cash/cash equivalents: no new debt or dilution implied
- Execution is discretionary (market conditions, price, availability), with Board retaining right to modify or cancel at any time
- Signals management confidence in stock valuation at current levels; buybacks reduce share count and can support EPS
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other OptimizeRx Corp 8-K filings
Get the next OPRX 8-K as it lands
Follow OPRX for push alerts, or ask the research agent what this filing means.